Orbital Decompression Surgery — Treatment Guide for Thyroid Eye Disease — Cost, Top Hospitals & Success Rates | MyMedicPlus

Orbital decompression surgery is an oculoplastic procedure that enlarges the bony orbit (the bony eye socket) and/or removes excess orbital fat to reduce proptosis (exophthalmos — protrusion of the eyeball forward from the bony socket), relieve pressure on the optic nerve, protect the cornea from exposure injury, and improve periorbital cosmesis in patients whose orbital volume has been increased by disease. The procedure is most commonly performed for thyroid eye disease (TED), also termed Graves' orbitopathy (GO) or thyroid-associated ophthalmopathy (TAO) — an autoimmune inflammatory condition affecting the orbit in patients with Graves' hyperthyroidism or, less commonly, Hashimoto's thyroiditis and even euthyroid individuals.

In thyroid eye disease, autoantibodies targeting the thyroid stimulating hormone receptor (TSHR) and insulin-like growth factor 1 receptor (IGF-1R) — expressed on orbital fibroblasts — trigger glycosaminoglycan accumulation, adipogenesis, and extraocular muscle volume expansion within the fixed bony orbital cavity. This increase in orbital tissue volume within a rigid bony compartment results in elevated orbital pressure, forward displacement of the globe (proptosis), compression of the optic nerve within the orbital apex, and restricted extraocular motility.

Orbital decompression relieves this pressure by surgically removing one or more walls of the bony orbit (allowing orbital contents to expand outward into adjacent spaces — the ethmoid sinuses, temporal fossa, or infra-orbital space) or by directly excising expanded orbital fat. The amount of proptosis reduction and the risk of complications depend on which walls are removed and the surgical technique employed.

Two clinical contexts drive orbital decompression planning: sight-threatening urgent decompression (for dysthyroid optic neuropathy or severe corneal exposure threatening vision, requiring surgery within days) and rehabilitative elective decompression (to correct cosmetically or functionally significant proptosis once the disease has entered the inactive phase, typically after 12–18 months of disease stability). The active versus inactive phase is assessed using validated scoring tools including the Clinical Activity Score (CAS) and EUGOGO disease severity classification before planning surgery.

Thyroid eye disease (TED/GO) is the primary indication for orbital decompression. A systematic understanding of its severity grading, activity assessment, and the associated ocular manifestations is essential for appropriate patient selection and timing of surgical intervention.

EUGOGO Severity Classification

The European Group on Graves' Orbitopathy (EUGOGO) classifies TED by severity into three levels:

• Mild TED: Minor eyelid retraction (<2 mm), mild soft tissue involvement, exophthalmos below the normal range for ethnicity, no diplopia or intermittent diplopia only, and no corneal exposure. Management is supportive (lubricant drops, UV-protective spectacles, smoking cessation); surgical intervention is not indicated unless the patient has significant psychosocial distress from mild proptosis.
• Moderate-to-severe TED: Eyelid retraction ≥2 mm, moderate or severe soft tissue involvement, exophthalmos above the normal range, inconstant or constant diplopia, and corneal exposure without corneal ulceration. Requires active medical treatment (IV glucocorticoids in the active phase) before consideration for rehabilitative decompression once inactive.
• Sight-threatening TED: Dysthyroid optic neuropathy (DON — compressive optic neuropathy from enlarged extraocular muscles at the orbital apex) or corneal breakdown (exposure keratopathy with ulceration threatening the visual axis). Requires urgent or emergency medical treatment (high-dose IV methylprednisolone) and, if no response within 2 weeks, immediate orbital decompression regardless of disease activity phase.

Clinical Activity Score (CAS)

The CAS is a validated 7-point scoring tool assessing the inflammatory activity of TED at the time of assessment. Points are awarded for: spontaneous orbital pain, pain on eye movement, eyelid redness, conjunctival injection, chemosis (conjunctival swelling), caruncle or plica inflammation, and periorbital oedema. A CAS of ≥3/7 defines active disease. Immunosuppressive treatment (IV glucocorticoids, rituximab, teprotumumab) is most effective during the active phase. Surgical rehabilitation is ideally deferred until CAS <3 (inactive disease) maintained for at least 3–6 months, ensuring disease has “burnt out” and surgical outcomes will be stable.

Proptosis Assessment

Hertel exophthalmometry measures the forward protrusion of the corneal apex relative to the lateral orbital rim. Normal values vary by ethnicity and sex: typically 12–20 mm in Caucasians and up to 23 mm in Black/African patients. Asymmetry >2 mm between orbits is clinically significant. High-resolution CT or MRI of the orbits quantifies orbital fat volume, extraocular muscle belly cross-sectional areas (diagnostic hallmark of TED: fusiform muscle belly enlargement sparing tendons), optic nerve stretch at the orbital apex, and bony orbital dimensions — all essential inputs for decompression planning.

Patient selection for orbital decompression requires clear identification of the clinical indication (urgent sight-threatening vs elective rehabilitative), confirmation that disease is in the appropriate phase (inactive for elective surgery), realistic patient expectations regarding outcome and post-operative strabismus risk, and optimisation of systemic thyroid status.

Urgent / emergency indications (operate regardless of disease activity):

• Dysthyroid optic neuropathy (DON): Compressive optic neuropathy from apex crowding by enlarged muscles, evidenced by deteriorating visual acuity, colour vision loss (desaturated red-green axis), relative afferent pupillary defect (RAPD), and visual field defects. After 2-week trial of high-dose IV methylprednisolone without improvement, emergency orbital decompression is performed.
• Severe corneal exposure with threatened ulceration: Lagophthalmos (inability to close the eyelids over the proptotic eye) causing corneal desiccation, breakdown, or ulceration threatening the visual axis requires urgent decompression to allow lid closure and corneal healing.

Elective / rehabilitative indications (inactive disease, CAS <3, stable for 3–6 months):

• Cosmetically or functionally unacceptable proptosis (Hertel >21 mm or significant asymmetry)
• Significant periorbital disfigurement causing psychosocial impairment
• Residual globe exposure after disease stabilisation with lubricant therapy
• Globe subluxation (extreme proptosis allowing globe displacement in front of the lids)

Pre-operative requirements:

• Euthyroid thyroid status — patients must have stable thyroid function (TSH, free T4, free T3 within reference range) before elective surgery. Active hyperthyroidism or hypothyroidism increases surgical risk and may destabilise the orbital disease.
• Smoking cessation — smoking is a strong independent risk factor for TED severity, treatment-resistance, and post-decompression suboptimal outcomes. Patients must be advised to stop smoking and offered cessation support.
• High-resolution orbital CT with axial and coronal reconstructions — mandatory for surgical planning to identify the medial, lateral, and floor walls, assess sinus anatomy, and plan the extent of bone removal.
• Formal ophthalmological assessment including BCVA, colour vision, visual fields, motility, and corneal assessment to document baseline function before surgery.

Multiple orbital decompression approaches exist, varying in the number of walls removed, the magnitude of proptosis reduction achievable, and the associated risk of post-operative diplopia from altered muscle alignment. Selection is based on the degree of proptosis to be corrected, the need to maximise decompression for optic neuropathy, patient anatomy, and surgeon preference.

Lateral Wall Decompression (Kronlein Approach)

The lateral orbital wall (greater wing of the sphenoid bone and zygomatic body) is removed through a lateral canthotomy or eyelid crease (hidden) incision. The temporalis fossa adipose tissue receives the displaced orbital contents. Proptosis reduction: approximately 2–3 mm per orbit. The lateral wall approach has a low risk of inducing post-operative diplopia compared to medial wall approaches because it does not directly disturb the medial or inferior rectus muscles. Often used as a first-line decompression for mild-to-moderate proptosis in patients without significant inferior or medial muscle enlargement, or as a complement to other approaches.

Medial Wall Decompression (Endoscopic Endonasal Approach)

The medial orbital wall (lamina papyracea of the ethmoid bone) is removed via an endoscopic transnasal route, displacing the orbital contents medially into the ethmoid sinuses. Proptosis reduction: approximately 2–3 mm per orbit. The endoscopic endonasal approach leaves no external scar and avoids skin incisions. It is well-suited for patients with significant medial wall and medial rectus involvement and is popular in centres with experienced rhinological surgeons. Risk of post-operative diplopia is significant (25–30%) as the medial rectus position is altered by medial expansion.

Balanced (Medial + Lateral Wall) Decompression

The most widely performed technique for moderate-to-severe TED proptosis. Combined removal of both the medial and lateral orbital walls creates balanced bilateral expansion of orbital contents into both the ethmoid sinuses and the temporal fossa, reducing proptosis by 3–5 mm per orbit while partially counterbalancing the motility disturbance each wall removal would cause if performed alone. The lateral wall component is usually accessed via a lateral canthotomy or upper eyelid crease incision; the medial wall is addressed endonasally or via a transcaruncular (hidden) approach. Balanced decompression is the current standard for rehabilitative decompression in most centres.

Three-Wall Decompression (Medial + Lateral + Floor)

Removing the orbital floor in addition to medial and lateral walls provides maximum proptosis reduction of 4–7 mm per orbit and is reserved for: severe DON where maximum decompression is required, large pre-operative proptosis (>25 mm Hertel), or revision decompression after a prior 2-wall procedure. The orbital floor (above the infra-orbital nerve and maxillary sinus) is removed through a lower eyelid (subciliary or transconjunctival) or transantral approach. Three-wall decompression carries the highest risk of post-operative diplopia (particularly hypotropia from inferior rectus displacement) — up to 50–60% of patients develop new or worsened diplopia requiring subsequent strabismus surgery.

Fat Decompression

In some TED patients, orbital fat expansion predominates over muscle belly enlargement. Orbital fat decompression — excising visible fat pads through transpalpebral (upper or lower eyelid) incisions without removing any bony wall — achieves 3–4 mm of proptosis reduction without altering the extraocular muscle positions. Fat decompression therefore carries a significantly lower risk of post-operative diplopia compared to bony decompression, and may be the preferred primary approach for cosmetic rehabilitation in patients with predominantly fat-predominant TED and no optic nerve involvement.

Orbital decompression achieves clinically and functionally significant improvements in proptosis, optic nerve function, corneal protection, and quality of life when the appropriate technique is matched to the clinical indication.

Proptosis reduction:

• Lateral wall only: approximately 2–3 mm reduction per orbit
• Medial wall only (endoscopic): approximately 2–3 mm reduction per orbit
• Balanced (medial + lateral): approximately 3–5 mm reduction per orbit — the most predictable and commonly targeted outcome
• Three-wall (medial + lateral + floor): approximately 4–7 mm reduction per orbit
• Fat decompression only: approximately 3–4 mm reduction without bony wall surgery

Dysthyroid optic neuropathy (DON): Orbital decompression is highly effective for DON. In cases that fail to respond to IV glucocorticoids, surgery reverses compressive optic neuropathy in 90–95% of cases when performed promptly. Visual acuity, colour vision, and visual fields typically recover within days to weeks of successful decompression if the optic nerve has not sustained irreversible damage from prolonged compression.

Corneal protection: Reducing proptosis restores orbital lid closure capacity, protecting the cornea from exposure damage and eliminating the risk of exposure keratopathy progression to corneal scarring or perforation.

Quality of life: Prospective quality-of-life studies using validated instruments (GO-QoL, Visual Function Questionnaire-25) consistently demonstrate substantial improvements in visual function, appearance-related anxiety, and social functioning after successful orbital decompression in TED patients. The severe psychosocial burden of disfiguring proptosis — including employment difficulties, social withdrawal, and depression — is often underappreciated and significantly improved by surgery.

Teprotumumab (non-surgical option — OPTIC trial): Teprotumumab is a monoclonal antibody targeting IGF-1R, approved in the USA (2020) for TED. The OPTIC trial (randomised, placebo-controlled) demonstrated a mean proptosis reduction of 2.82 mm in the active treatment arm versus 0.54 mm placebo — a clinically meaningful non-surgical alternative for active moderate-to-severe TED. Teprotumumab is discussed further in the alternatives section as it may reduce or eliminate the need for decompression surgery in appropriately selected active-phase patients.

Orbital decompression is a well-established procedure with a favourable safety profile in experienced oculoplastic hands. However, procedure-specific risks must be carefully discussed with each patient before consent, as some complications significantly affect the post-operative management pathway.

Post-operative diplopia (the principal functional risk): New or worsened diplopia is the most clinically important complication of orbital decompression and the major determinant of the post-operative management sequence. By altering the mechanical relationships between the extraocular muscles and their bony orbital walls, decompression changes the alignment of the eyes and the balance of muscle forces.

• Lateral wall only: approximately 10–15% risk of new diplopia
• Medial wall (endoscopic): approximately 25–30% risk of new diplopia
• Balanced (medial + lateral): approximately 20–30% risk — better than the sum of individual risks due to partially counterbalancing effects
• Three-wall: approximately 50–60% risk of new or worsened diplopia
• Fat decompression: lowest risk, approximately 5–10%

Post-decompression diplopia is managed by strabismus surgery (extraocular muscle recession/resection), but crucially this must be deferred until proptosis reduction has stabilised — conventionally at 6 months after decompression. The sequence is therefore: decompression → wait 6 months → strabismus surgery if diplopia persists → eyelid surgery for residual retraction and cosmesis. Performing strabismus surgery before complete orbital stabilisation risks having to re-operate as the alignment continues to change.

Other surgical risks:

• Visual deterioration / blindness: Very rare (<0.5%) but serious. Can occur from direct intraoperative optic nerve injury, post-operative haematoma causing orbital compartment syndrome (acute pressure rise), or iatrogenic damage to the optic nerve at the orbital apex. Any new visual loss after orbital surgery is a surgical emergency requiring immediate CT imaging and, if haematoma is confirmed, bedside canthotomy/cantholysis to decompress the orbit before formal re-exploration.
• Cerebrospinal fluid (CSF) leak: Rarely, when the medial wall is removed aggressively and the cribriform plate or anterior ethmoidal roof is violated. Managed initially conservatively; surgical repair (neurosurgical or endoscopic) is required for persistent leak.
• Infraorbital nerve paraesthesia: Following orbital floor removal, temporary or permanent numbness of the cheek and upper lip on the ipsilateral side may occur due to infra-orbital nerve traction or trauma.
• Enophthalmos: Over-decompression can cause the globe to sink too deeply into the socket (enophthalmos), which is cosmetically unacceptable and functionally significant. Careful pre-operative planning and conservative bony removal reduce this risk.
• Sinusitis or mucocele formation: After medial wall or floor removal with exposure of the paranasal sinuses, secretion drainage may be impaired. Antibiotic cover perioperatively and intranasal steroid post-operatively mitigate this risk.

The post-operative management of orbital decompression requires understanding of the planned rehabilitation sequence — decompression, then strabismus surgery if needed, then eyelid surgery — with defined waiting periods between stages to allow orbital and muscular stabilisation.

Immediate post-operative period:

• Orbital ice compresses for the first 24–48 hours reduce post-operative swelling and haemorrhage risk
• Head elevation (30–45 degrees) in the immediate recovery period reduces orbital oedema
• Topical antibiotic drops or ointment as prescribed; oral antibiotics if endonasal approach was used
• Patients must be warned to report immediately any sudden severe eye pain, marked visual deterioration, or inability to open the eye — symptoms of orbital haemorrhage requiring emergency decompression (canthotomy)
• Systemic corticosteroids (short oral course) are often prescribed to minimise post-operative inflammatory oedema

First post-operative review (week 1–2): Assessment of visual acuity, IOP, proptosis measurement (Hertel), and motility. The degree of early proptosis reduction and any diplopia are documented. Residual oedema in the early weeks means final proptosis measurement and motility assessment are not possible at this stage.

Stabilisation assessment (3–6 months): The critical review for determining whether strabismus surgery is needed. Formal orthoptic assessment (cover test, prism testing, Hess chart, field of single binocular vision) characterises the diplopia pattern and its functional impact. If significant diplopia in the primary or reading positions persists, strabismus surgery is planned — but not performed until at least 6 months post-decompression to ensure orbital stability.

Strabismus surgery timing and sequencing: Strabismus surgery (extraocular muscle recession, resection, or adjustable suture techniques) is performed as a separate procedure at ≥6 months post-decompression, once proptosis and motility measurements have been stable for at least 2–3 months. Adjustable suture techniques, which allow fine-tuning of muscle position in the immediate post-operative period under topical anaesthesia, are preferred by many strabismologists for TED strabismus because of the inherent unpredictability of muscle response.

Eyelid surgery timing: Upper eyelid retraction correction (lateral tarsorrhaphy, levator recession, or Mullerectomy) and lower eyelid elevation procedures are performed as the final stage of the TED rehabilitation sequence — typically at 3–6 months after strabismus surgery or, if strabismus surgery was not required, at 6 months after decompression. Premature eyelid surgery before complete orbital stabilisation risks unsatisfactory or asymmetric results.

Orbital decompression surgery costs vary significantly based on the number of walls decompressed, whether it is performed as an emergency or elective procedure, anaesthetic requirements, hospital stay, and geographic location. The complete TED rehabilitation sequence — including decompression, potential strabismus surgery, and eyelid surgery — may require three separate operations over 12–18 months, multiplying the total cost estimate.

Key cost-influencing factors:

• Procedure complexity: Lateral wall-only decompression is less technically demanding than 3-wall decompression; 3-wall procedures with floor removal through a transconjunctival approach require greater surgical time and expertise, increasing operative costs.
• Surgical approach combination: Balanced decompression using both an endoscopic endonasal approach (for medial wall) and an external approach (for lateral wall) may require joint surgeon teams (oculoplastic + rhinological), increasing operative fees.
• Emergency vs elective: Emergency decompression for DON or acute corneal exposure, performed outside standard operating lists, carries higher facility and anaesthesia costs than planned elective procedures.
• Hospital stay: Most orbital decompression procedures are performed as day surgery or with 1-night admission. Complex 3-wall decompressions with sinus surgery may require 1–2 nights. Strabismus surgery is commonly day-case. Eyelid surgery may be under local anaesthesia as an outpatient procedure.
• Post-operative imaging: CT scan at 3–6 months to document bone remodelling and confirm structural outcomes adds to total management cost.
• Teprotumumab cost: In countries where teprotumumab is approved, the drug cost is substantial (approximately USD 200,000–300,000 per treatment course in the USA). This must be weighed against the cost savings of potentially avoiding surgical decompression. Access varies internationally; teprotumumab is not approved in the UK or EU as of 2026.

International access: Oculoplastic and orbital surgery of the standard required for TED management is available at specialist centres worldwide. JCI-accredited eye hospitals in India (Chennai, Mumbai, Hyderabad), Singapore, and Thailand offer orbital decompression at 40–65% lower cost than equivalent procedures in the USA or UK, with experienced orbital surgeons who have subspecialty training in oculoplastics and TED management. Patients travelling internationally for elective decompression should ensure a clear plan for the complete rehabilitation sequence and follow-up availability.

The management of thyroid eye disease has been transformed by the availability of targeted biologic therapy, offering clinically significant non-surgical options that may substantially reduce the need for, or magnitude of, orbital decompression in appropriately selected patients.

Teprotumumab (Tepezza — IGF-1R monoclonal antibody): The landmark OPTIC randomised controlled trial (Kossler et al., 2020, published in Ophthalmology) demonstrated that teprotumumab achieved a mean proptosis reduction of 2.82 mm versus 0.54 mm for placebo after 8 infusions over 24 weeks in patients with active, moderate-to-severe TED — a clinically meaningful and statistically highly significant result. Additionally, 83% of teprotumumab-treated patients achieved a ≥2 mm proptosis reduction versus 10% in the placebo arm. Secondary endpoints including CAS reduction, diplopia improvement, and quality-of-life measures also strongly favoured teprotumumab. The drug is FDA-approved in the USA and is now considered the first-line treatment for active moderate-to-severe TED in countries where it is available and funded, potentially reducing or eliminating the need for surgical decompression in this indication.

Side effects of teprotumumab include infusion reactions, hearing loss/tinnitus (requires audiological monitoring), hyperglycaemia (requires glucose monitoring, particularly in diabetic patients), muscle cramps, nausea, and alopecia. The drug is contraindicated in pregnancy. Post-treatment relapse of TED can occur, and the role of retreatment courses is being evaluated in ongoing studies.

Intravenous methylprednisolone (IV GCs): High-dose IV glucocorticoid pulses (typically 500 mg methylprednisolone weekly for 6 weeks, then 250 mg weekly for 6 weeks — the “EUGOGO schedule”) remain the most widely used first-line treatment for active moderate-to-severe TED in countries without teprotumumab access. IV GCs are superior to oral prednisolone for soft tissue inflammation, proptosis, and diplopia improvement; they reduce CAS rapidly in most patients. However, they do not achieve the magnitude of proptosis reduction that teprotumumab or surgery can provide, and their effects on extraocular muscle volume are modest.

Rituximab: An anti-CD20 monoclonal antibody depleting B-lymphocytes, used as a second-line immunosuppressant for active TED refractory to IV glucocorticoids. EUGOGO consensus guidelines include rituximab as an option in this setting. Proptosis reduction is less consistent than with teprotumumab.

Selenium supplementation: A randomised controlled trial (Marcocci et al., NEJM 2011) demonstrated that selenium 200 mcg/day for 6 months significantly improved outcomes in mild active TED compared to placebo, reducing progression to more severe disease and improving quality of life. Recommended by EUGOGO for mild active TED.

Smoking cessation: Smoking is the most powerful modifiable risk factor for TED severity, treatment resistance, and poor surgical outcomes. Smoking cessation advice and pharmacological support are mandatory components of TED management, not merely adjunctive recommendations.

Radiotherapy: Orbital radiotherapy (20 Gy in 10 fractions) has been used for moderate-to-severe active TED, with modest benefit for soft tissue inflammation and diplopia but limited effect on proptosis. It is generally reserved for patients who are refractory to or intolerant of immunosuppression, contraindicated in patients under 35 years or with diabetes (retinopathy risk from radiation) and in those with optic nerve disease.